Effects of orally administered bovine lactoferrin and lactoperoxidase on influenza virus infection in mice.
Milk contains a wide variety of host protective factors against infectious microbes. Among these protective factors, lactoferrin (LF) and lactoperoxidase (LPO) have been reported to exhibit antiviral activities as well as immuno-modulatory effects. In the present study, the effects of orally administered LF and LPO were assessed in a mouse influenza virus infection model. BALB/c mice were intranasally infected with 6.6x10(2) p.f.u. of influenza virus A/PR/8/34(H1N1). Bovine LF or LPO was administered once daily at a dose of 62.5 mg per mouse by gavage, starting 1 day before infection. Mice given LF or LPO showed a significantly lower lung consolidation score on day 6 after infection compared with the control mice that were given water instead. Concurrently, the number of infiltrated leukocytes recovered from bronchoalveolar lavage fluid (BALF) on day 6 was significantly lower in mice given LF or LPO. However, the virus yield in the BALF was not affected by these treatments. The serum level of IL-6, a pro-inflammatory cytokine, positively correlated with the lung consolidation score in each group and was significantly lower on day 6 in the mice given LPO. These results suggest the potential of oral administration of LF or LPO to attenuate pneumonia in influenza-virus-infected mice through the suppression of infiltration of inflammatory cells in the lung.
Shin
Kouichirou
K
Nutritional Science Laboratory, Morinaga Milk Industry Co. Ltd, 5-1-83 Higashihara, Zama, Kanagawa 228-8583, Japan 2Department of Virology, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama, Toyama 930-0194, Japan.
Wakabayashi
Hiroyuki
H
Nutritional Science Laboratory, Morinaga Milk Industry Co. Ltd, 5-1-83 Higashihara, Zama, Kanagawa 228-8583, Japan 2Department of Virology, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama, Toyama 930-0194, Japan.
Yamauchi
Koji
K
Nutritional Science Laboratory, Morinaga Milk Industry Co. Ltd, 5-1-83 Higashihara, Zama, Kanagawa 228-8583, Japan 2Department of Virology, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama, Toyama 930-0194, Japan.
Teraguchi
Susumu
S
Nutritional Science Laboratory, Morinaga Milk Industry Co. Ltd, 5-1-83 Higashihara, Zama, Kanagawa 228-8583, Japan 2Department of Virology, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama, Toyama 930-0194, Japan.
Tamura
Yoshitaka
Y
Nutritional Science Laboratory, Morinaga Milk Industry Co. Ltd, 5-1-83 Higashihara, Zama, Kanagawa 228-8583, Japan 2Department of Virology, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama, Toyama 930-0194, Japan.
Kurokawa
Masahiko
M
Nutritional Science Laboratory, Morinaga Milk Industry Co. Ltd, 5-1-83 Higashihara, Zama, Kanagawa 228-8583, Japan 2Department of Virology, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama, Toyama 930-0194, Japan.
Shiraki
Kimiyasu
K
Nutritional Science Laboratory, Morinaga Milk Industry Co. Ltd, 5-1-83 Higashihara, Zama, Kanagawa 228-8583, Japan 2Department of Virology, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama, Toyama 930-0194, Japan.
D000284:Administration, Oral; D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004195:Disease Models, Animal; D007781:Lactoferrin / Q000008:administration & dosage / Q000627:therapeutic use*; D007784:Lactoperoxidase / Q000008:administration & dosage / Q000627:therapeutic use*; D051379:Mice; D009975:Orthomyxoviridae; D009976:Orthomyxoviridae Infections / Q000188:drug therapy* / Q000401:mortality
D000998:Antiviral Agents; D007784:Lactoperoxidase; D007781:Lactoferrin